Ser70

Site Information
SRGRLRLsCLDLEQC SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 11091578

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , NCI-H3255 (pulmonary) ( 2 , 3 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Possemato A (2009) CST Curation Set: 7405; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
3	Possemato A (2009) CST Curation Set: 7399; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info